Treatment of Eales Disease in Active Retinal Perivasculitis (Inflammatory Stage)

Clinical Scenario

This protocol addresses the management of Eales disease presenting in the active retinal perivasculitis stage — the inflammatory phase — in patients without a positive Mantoux test. Controlling active retinal inflammation is the central clinical priority in this setting.

Condition Details

Systemic corticosteroids have been established as the mainstay of therapy during the active perivasculitis stage of Eales disease. However, not all patients respond adequately or can tolerate prolonged corticosteroid use.

Treatment Approach (Partial)

When corticosteroid therapy is insufficient or not tolerated, the management approach for this stage involves consideration of immunosuppressive agents. The complete structured regimen — including specific agent selection, sequencing, and clinical decision criteria — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Corticosteroids remain the mainstay of therapy in the active perivasculitis stage of Eales disease.

Systemic corticosteroids have been found to be beneficial in the active perivasculitis stage.

In patients who do not respond to systemic steroids or have unacceptable side effects due to oral corticosteroids, we recommend usage of immunosuppressive agents like cyclosporine or azathioprine.

DOI: 10.1016/s0039-6257(02)00288-6

View source ↗